Retirement Systems of Alabama Sells 4,246 Shares of Halozyme Therapeutics, Inc. $HALO

Retirement Systems of Alabama trimmed its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 380,379 shares of the biopharmaceutical company’s stock after selling 4,246 shares during the period. Retirement Systems of Alabama owned approximately 0.31% of Halozyme Therapeutics worth $19,787,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Wealth Preservation Advisors LLC bought a new position in shares of Halozyme Therapeutics in the first quarter worth approximately $32,000. SVB Wealth LLC bought a new position in shares of Halozyme Therapeutics in the first quarter worth approximately $33,000. Bessemer Group Inc. increased its position in shares of Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 207 shares during the last quarter. Brooklyn Investment Group increased its position in shares of Halozyme Therapeutics by 1,558.1% in the first quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 670 shares during the last quarter. Finally, CWM LLC increased its position in shares of Halozyme Therapeutics by 46.3% in the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 438 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Nicole Labrosse sold 2,227 shares of the firm’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $77.95, for a total value of $173,594.65. Following the completion of the sale, the chief financial officer owned 22,079 shares of the company’s stock, valued at $1,721,058.05. This trade represents a 9.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $69.03, for a total value of $1,380,600.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at $50,648,622.57. The trade was a 2.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 108,227 shares of company stock valued at $7,779,595 over the last quarter. 2.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Weiss Ratings cut shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. The Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They set a “neutral” rating and a $55.00 price target on the stock. Leerink Partners upgraded shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target on the stock in a research report on Tuesday, October 14th. Zacks Research cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Finally, JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research report on Monday, October 27th. Four analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Hold” and an average target price of $73.11.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $65.19 on Friday. The firm has a market cap of $7.63 billion, a PE ratio of 14.92, a price-to-earnings-growth ratio of 0.35 and a beta of 1.16. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $79.50. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The business has a 50 day moving average price of $71.16 and a 200-day moving average price of $62.52.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.